Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?
The impact of ER levels on the response to tamoxifen was evaluated in 1,623 postmenopausal primary breast cancer patients treated at our center (median follow-up 8.2 years). In patients receiving adjuvant tamoxifen a significantly longer disease-free survival (DFS) was observed when ER levels were elevated (p<0.00001). Very high ER (>424 fmol/mg protein) appeared to be detrimental in node-negative patients not treated with tamoxifen.
Floiras
J L
JL
Department of Radiotherapy, Centre René Huguenin, St-Cloud, France.
Hacene
K
K
Turpin
F
F
Spyratos
F
F
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004341:Drug Evaluation; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004967:Estrogens; D005260:Female; D006801:Humans; D015993:Life Tables; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology; D015411:Mastectomy, Modified Radical; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017698:Postmenopause; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D012189:Retrospective Studies; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D004967:Estrogens; D009363:Neoplasm Proteins; D011960:Receptors, Estrogen; D013629:Tamoxifen